此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Initial Study of a MOTHER-DAUGHTER SIDE-BRANCH ACCESS™ DES System (FIH Feasibility Study)

2026年6月25日 更新者:Advanced Bifurcation Systems Inc.

Initial Study of a MOTHER-DAUGHTER SIDE-BRANCH ACCESS™ DES System for Bifurcation Lesions (First-in-Human, Feasibility Study)

This first in human feasibility study is designed to evaluate the feasibility MD-SBA DES in subjects undergoing percutaneous coronary intervention (PCI) to treat bifurcation lesions.

研究概览

详细说明

This is a prospective, single-arm, single-center initial feasibility clinical study enrolling subjects with symptomatic ischemic heart disease due to a de novo coronary bifurcation lesion. The objective is to obtain initial insights into the clinical safety of the device-specific aspects of the procedure; whether the device can be successfully delivered and implanted; whether there are any operator technique challenges with device use; human factors; clinical safety of the device and whether the device performs in accordance with its intended purpose.

All enrolled subjects will be treated with the study device during the index procedure and followed after treatment to assess procedural success, clinical safety, and device performance. Follow-up is conducted through 3 years.

研究类型

介入性

注册 (实际的)

13

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Asunción、巴拉圭
        • Cirugía Cardiovascular, Sanatorio Italiano

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Be 21 years of age or older. Have symptomatic ischemic heart disease or objective evidence of reduced blood flow to the heart.

Be eligible for PCI, also known as coronary stenting. Have a new coronary artery narrowing involving a branch point that meets the study's angiographic requirements.

Be willing and able to complete study follow-up. Be able to provide written informed consent. If able to become pregnant, have a negative pregnancy test before the procedure and agree not to become pregnant or breastfeed for 1 year.

Exclusion Criteria:

Are currently participating in another investigational drug or device study that could interfere with this study.

Had a coronary intervention within 30 days before the planned study procedure. Need a planned additional coronary procedure soon after the study procedure. Had a prior stent placed close to the target lesion. Have a target lesion that requires certain other treatment devices before stent placement, other than balloon angioplasty or intravascular lithotripsy.

Have a serious medical condition that could limit participation, follow-up, or interpretation of the study results.

Have a life expectancy of less than 3 years. Have a condition requiring chronic immunosuppressive therapy or have a severe autoimmune or immunosuppressive condition.

Have significantly reduced heart pumping function. Had a recent acute heart attack, unless certain laboratory values have returned to acceptable levels.

Had a stroke or transient ischemic attack within the past 6 months. Have certain abnormal blood test results, including low white blood cell count, low neutrophil count, low platelet count, or significantly reduced kidney function.

Have active stomach or intestinal bleeding, active peptic ulcer disease, a bleeding disorder, or cannot receive blood transfusions.

Have a known allergy or contraindication to required medications, contrast dye, or study device materials that cannot be adequately managed.

Are pregnant, breastfeeding, or planning to become pregnant within 1 year after the study procedure.

Have coronary anatomy that is not suitable for the study device, as determined during coronary angiography (This may include blood clot in the target lesion, severe vessel tortuosity, severe calcification, certain lesion locations, or other significant disease in the target vessel).

Are unable or unwilling, in the opinion of the study doctor, to comply with the study requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Patients with coronary bifurcation lesions
Patients undergoing PCI to treat a bifurcation lesion
The MD-SBA DES System is a single use, minimally invasive combination product that consists of a cobalt chromium metal coronary stent, coated with sirolimus in a PEA/BHT matrix, on a rapid exchange (RX) delivery system.
其他名称:
  • Percutaneous coronary Intervention (PCI)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Procedure Success
大体时间:Periprocedural
To determine whether the device can be successfully delivered and implanted, as measured by attainment of <30% final residual stenosis of the target lesion and no in-hospital major adverse cardiac events (MACE).
Periprocedural

次要结果测量

结果测量
措施说明
大体时间
MACE
大体时间:30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
Percentage of subjects with major adverse cardiac events, defined as cardiac death, myocardial infarction, emergency coronary artery bypass surgery, or clinically driven target lesion revascularization. Components of MACE, including cardiac death and myocardial infarction, may also be summarized.
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
TVF
大体时间:30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
Percentage of subjects with target vessel failure, defined as cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization.
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
Target Lesion Revascularization of the Side Branch
大体时间:30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
Percentage of subjects requiring repeat treatment of the side branch by percutaneous or surgical methods.
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
Stent thrombosis
大体时间:6-months, 1-year, 2-years, and 3-years post index procedure
Percentage of subjects with late stent thrombosis.
6-months, 1-year, 2-years, and 3-years post index procedure
Acute Success
大体时间:Index procedure
Percentage of subjects with successful device delivery and target lesion treatment, including final residual stenosis <30% and adequate side branch flow.
Index procedure
Side Branch Access
大体时间:Index procedure
Percentage of subjects with TIMI-3 flow in the side branch and/or need to re-cross the side branch after study device use.
Index procedure
Bleeding / Vascular Complications
大体时间:Hospital discharge
Percentage of subjects with bleeding or vascular complications.
Hospital discharge
Procedure Time
大体时间:Index procedure
Duration of the index procedure in minutes
Index procedure
Fluoroscopy Time
大体时间:Index procedure
Total fluoroscopy duration during index procedure in minutes
Index procedure
Contrast Volume
大体时间:Index procedure
Total volume of contrast media used during index procedure in milliliters
Index procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Randy E David, PhD、Advanced Bifurcation Systems Inc.
  • 学习椅:Mehran Khorsandi, MD、Advanced Bifurcation Systems Inc.
  • 首席研究员:Adrian Ebner, MD、Sanatorio Italiano, Asunción, Paraguay

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月16日

初级完成 (实际的)

2025年11月19日

研究完成 (估计的)

2028年11月19日

研究注册日期

首次提交

2026年5月21日

首先提交符合 QC 标准的

2026年6月11日

首次发布 (实际的)

2026年6月16日

研究记录更新

最后更新发布 (实际的)

2026年6月29日

上次提交的符合 QC 标准的更新

2026年6月25日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅